Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

3H-Spiperone labels sigma receptors, not dopamine D2 receptors, in rat and human lymphocytes.

Authors
Coccini-T; Manzo-L; Costa-LG
Source
Immunopharmacology 1991 Sep-Oct; 22(2):93-105
NIOSHTIC No.
00235444
Abstract
The characteristics of the binding of tritium (H3) labeled spiperone (749020) in lymphocytes was investigated, as part of a larger study aimed at exploring the potential use of neurotransmitter receptors in circulating blood cell as markers for the same receptors in solid tissues. Adult male Sprague-Dawley-rat spleen lymphocytes or human blood lymphocytes were used in binding assays. The findings suggested that H3 labeled spiperone binds to a high affinity, saturable site in rat and human lymphocytes. The binding was similar at either 37 or 4 degrees-C, suggesting that the observed binding was not due to nonspecific trapping of H3 labeled spiperone into the cell or to a specific uptake system. The binding was saturable in a range of concentrations between 0.5 and 50 nanomolar; however, the dissociation constant was about 40 fold higher than that of H3 labeled spiperone in striatum. The authors conclude that H3 labeled spiperone labels a population of sites in rat and human lymphocytes which can be better characterized as sigma receptors rather than dopamine D2 receptors. These findings also suggest that changes in H3 labeled spiperone binding observed in lymphocytes from schizophrenic patients may represent changes in sigma receptors in these cells.
Keywords
NIOSH-Publication; NIOSH-Grant; Neurotoxic-effects; Laboratory-animals; Blood-cells; In-vitro-studies
Contact
Environmental Health University of Washington Dept/environmental Hlth/sc-34 Seattle, WA 98195
CODEN
IMMUDP
CAS No.
749-02-0
Publication Date
19910901
Document Type
Journal Article
Funding Amount
272792
Funding Type
Grant;
Fiscal Year
1991
NTIS Accession No.
NTIS Price
Identifying No.
Grant-Number-R01-OH-02629
Issue of Publication
2
ISSN
0162-3109
Priority Area
Neurotoxic Disorders; Neurotoxic-effects
Source Name
Immunopharmacology
State
WA
Performing Organization
University of Washington, Seattle, Washington
TOP